Ruoslahti successfully engineered a new peptide chain that, after being injected into a mouse’s bloodstream, could find its way to the mouse’s tumor faster and more effectively than anything seen before. That, by itself, would have constituted a significant advance. But Ruoslahti also noticed that his new peptide chain exhibited what he termed several “unexpected and remarkable properties.” Not only did the chain function as a superior homing agent, finding and adhering to the tumor, but it also managed to penetrate the tumor as well. “It spread into the tumor in ways we had not seen before,” Ruoslahti recounted. The one-two punch packed by Ruoslahti’s peptide chain — described in the scientific literature as “iRGD”
They still have to go a long way through safety and efficacy trials on humans before it can be approved by FDA for common use, if the license is applied for. This takes eons! The bedst way for a fast commercialization is to try this drug outside U.S.A.